secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001619856-26-000012
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou gets RMAT designation from FDA for CB-011 in relapsed/refractory multiple myeloma
--------------------------------------------------------------------------------

- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for CB-011 allogeneic anti-BCMA CAR-T.
- RMAT based on CaMMouflage phase 1 dose escalation data: 92% ORR, 75% ≥CR, 91% MRD negativity in 12 BCMA-naïve patients at RDE.
- No graft-versus-host disease or certain neurotoxicities observed; manageable safety profile reported.
- Dose expansion enrollment ongoing for both BCMA-naïve and BCMA-exposed cohorts; additional data expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000012/0001619856-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000012/crbu-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001619856-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer